News

November 2024

Nitrofurantoin Oral Suspension, USP 25mg/ 5 mL was launched in the US markets.

Carnegie Pharmaceuticals has acquired six (6) products.

Erythromycin Ethylsuccinate for oral Suspension USP, 200 mg/5 mL and 400 mg/5 mL (NDA Product; Eryped® 200 and Eryped® 400)

Erythromycin Ethylsuccinate Film-Coated Tablets USP, 400 mg (E.E.S. 400®)

Erythromycin Delayed Release Tablets USP, 250 mg, 333 mg and 500 mg (ERY-TAB®)

Erythromycin Delayed Release Pellets USP, 250 mg

Erythromycin Film-Coated Tablets USP, 250 mg & 500 mg

Erythromycin Stearate Tablets USP, 250 mg

Our commercial plan is to launch Eryped Oral Suspension and E.E.S 400 Tablets in December 2024, and the remaining products in 2025.  For more information about these products, please call our sales team member, Paul Krauthauser at 267-772-0879 or Micthell Goldberg at 267-679-3008.

October 2024

Carnegie Pharmaceuticals LLC received approval for Nitrofurantoin Oral Suspension USP, 25 mg/5 mL from US-FDA.

September 2024

Carnegie Pharmaceuticals LLC announced submission of an ANDA product to US FDA.

FDA approved Metyrosine Capsules that was developed and commercially manufactured by Carnegie Pharmaceuticals, LLC for Leading Pharma, LLC.

August 2024

Carnegie Pharmaceuticals LLC announced submission of an ANDA product to US FDA.

August 2024

Carnegie Pharmaceuticals launched Primidone Tablets USP, 50 mg & 250 mg.

July 2024

Carnegie Pharmaceuticals LLC announced submission of an ANDA product to US FDA.

June 2024

Carnegie Pharmaceuticals LLC announced submission of an ANDA product to US FDA.

May 2024

Carnegie Pharmaceuticals LLC announced submission of an ANDA product to US FDA.

March 2024

Carnegie Pharmaceuticals LLC announced submission of an ANDA product to US FDA.

Carnegie Pharmaceuticals LLC received approval for Oxcarbazepine Oral Suspension USP, 300 mg/5 mL from USA FDA.

Feb 2024

Carnegie Pharmaceuticals LLC received approval for Liothyronine Sodium Tablets USP, 5 mcg, 25 mcg & 50 mcg from US FDA.

Jan 2024

• Carnegie Pharmaceuticals started Sales and Marketing department to sell products under its own label.
• Paul Krauthauser joined Carnegie Pharmaceuticals as a Chief Commercial Officer.

Dec 2023

Carnegie Pharmaceuticals LLC acquired three approved products given below.  The plan is to launch these products by the end of 2024.

• Letrozole Tablets, 2.5 mg
• Rasagiline Mesylate Tablets, 0.5 mg & 1 mg
• Latanoprost Ophthalmic Solution, 0.005%

July 2023

• Carnegie Pharmaceuticals successfully completed Pre-Approval Inspection (PAI).
• Carnegie Pharmaceuticals received approval for Famotidine Oral Suspension USP, 40mg/5ml from US FDA.

March 2023

Carnegie Pharmaceuticals, LLC announced submission of an ANDA product to US FDA.

February 2023

Carnegie Pharmaceuticals, LLC announced submission of an ANDA product to US FDA.

January 2023

Carnegie Pharmaceuticals, LLC announced submission of an ANDA product to US FDA.

December 2022

Carnegie Pharmaceuticals, LLC signed a contract to supply its products in Chile.

June 2022

• Carnegie Pharmaceuticals acquired ANDA for Aminocaproic Acid Tablets USP, 1000mg and Aminocaproic Acid Tablets USP, 500mg. 
• Carnegie Pharmaceuticals acquired ANDA for Aminocaproic Acid Solution USP, 0.25g/ml.

April 2022

Carnegie Pharmaceuticals is pleased to announce the approval of Etravirine Tablets, 100mg and 200mg.

March 2022

FDA approved Oseltamivir Phosphate for Oral Suspension, 6 mg/mL that was developed and commercially manufactured by Carnegie Pharmaceuticals, LLC for Leading Pharma, LLC.

February 2022

Carnegie Pharmaceuticals, LLC announced submission of an ANDA product to the US FDA.

November 2021

Carnegie Pharmaceuticals, LLC successfully completed FDA inspection (GMP and PAI) without any observations.

October 2021

Carnegie Pharmaceuticals, LLC announces the submission of an ANDA product that was manufactured at its facilities and filed by its partner, Leading Pharma, LLC.

July 2021

Leading Pharma commercially launches Aminocaproic Acid Tablets USP, 500mg and 1000mg that is manufactured at Carnegie Pharma facilities.

June 2021

Carnegie Pharmaceuticals, LLC succesfully completed the pre-approval inspection by the FDA.

May 2021

• Carnegie Pharmaceuticals, LLC announces the submission of an ANDA product that was manufactured at its facilities and filed by its partner, Leading Pharma, LLC.
• Leading Pharma commercially launches Aminocaproic Acid Oral Solution, 1.25g/5mLthat is manufactured at Carnegie Pharma facilities.

March 2021

FDA approved Doxepin Hydrochloride Capsules USP, 10 mg , 25 mg , 50 mg , 75 mg , 100 mg , that was developed by Carnegie Pharmaceuticals, LLC for Leading Pharma, LLC.

March 2021

FDA approved Doxepin Hydrochloride Capsules USP, 150 mg, that was developed by Carnegie Pharmaceuticals, LLC for Leading Pharma, LLC.

February 2021

FDA approved Aminocaproic Acid Tablets USP, 500mg and 1000mg that was developed and manufactured by Carnegie Pharmaceuticals, LLC for Leading Pharma, LLC.

January 2021

FDA approved Aminocaproic Acid Oral Solution, 1.25g/5mL that was developed and manufactured by Carnegie Pharmaceuticals, LLC for Leading Pharma, LLC.

December 2020

Carnegie Pharmaceuticals, LLC received DEA Manufacturing License (Schedule 2-5).

October 2020

Carnegie Pharmaceuticals, LLC announces the submission of an ANDA product that was manufactured at its facilities and filed by its partner, Leading Pharma, LLC.

September 2020

Carnegie Pharmaceuticals successfully completed its first FDA inspection.

July 2020

Carnegie Pharmaceuticals LLC signed an agreement with Alter Pharma, Belgium to develop and commercially manufacture a NDA product for the US market.

April 2020

• FDA approved Hydroxyurea Capsules, 500 mg, that was developed by Carnegie Pharmaceuticals, LLC for Leading Pharma, LLC.
• FDA approved Oxybutynin Chloride Tablets, 5 mg, that was developed by Carnegie Pharmaceuticals, LLC for Leading Pharma, LLC.
• Carnegie Pharmaceuticals, LLC announces the submission of an ANDA product that was developed at its R&D facilities and filed by its partner, Leading Pharma, LLC.

February 2020

FDA approved Clomipramine Hydrochloride Capsules, 25 mg, 50 mg and 75 mg, that was developed by Carnegie Pharmaceuticals, LLC for Leading Pharma, LLC.

November 2019

Carnegie Pharmaceuticals, LLC announces the submission of an ANDA product that was manufactured at its facilities and filed by its partner, Leading Pharma, LLC.

June 2019

Carnegie Pharmaceuticals, LLC announces the submission of an ANDA product that was developed at its R&D facilities and filed by its partner, Leading Pharma, LLC.

December 2018

Carnegie Pharmaceuticals, LLC announces the completion of the manufacturing plant located at its Delran Facilities.

October 2018

Carnegie Pharmaceuticals, LLC announces the submission of an ANDA product that was developed at its R&D facilities and filed by its partner, Leading Pharma, LLC.

May 2018

Carnegie Pharmaceuticals has moved to a 50,000 square feet facility in Delran, NJ. The new facility has state of the art laboratories and manufacturing capabilities in the solid and liquid dosage forms.

April 2018

Carnegie Pharmaceuticals, LLC announces the submission of an ANDA product that was developed at its R&D facilities and filed by its partner, Leading Pharma, LLC.

March 2018

• Carnegie Pharmaceuticals, LLC announces the submission of the second ANDA product that was developed at its R&D facilities and filed by its partner, Leading Pharma, LLC. 
• Carnegie Pharmaceuticals appoints Punit Prajapati as the Associate Director of Operations. Mr. Prajapati previously worked as the Manager, MSTG (Manufacturing, Science and Technology Group) at Sun Pharmaceuticals, Inc.

December 2017

Carnegie Pharmaceuticals, LLC announces the submission of the first ANDA product that was developed at its R&D facilities and filed by its partner, Leading Pharma, LLC.

August 2017

Carnegie Pharmaceuticals acquired its future manufacturing facility. The facility is approximately 50,000 square feet located in Southern New Jersey. This facility will enable Carnegie to file and commercially supply products to the market from its own site.

May 2017

Carnegie Pharmaceuticals appoints Dr. Venkat Dandu as the Asst. Manager of Analytical Research & Development. Dr. Dandu previously worked in the Analytical R&D department for more than 10 years at Lupin Pharma and Oncova Therapeutics.

March 2017

Carnegie Pharmaceuticals appoints Sumreen Naqvi as the Manager of Analytical Research & Development. Ms. Naqvi previously worked in the analytical research and development department of Johnson and Johnson, Sun Pharma (formerly URL Mutual) and Teva Pharmaceuticals (formerly Barr Labs).

March 2017

Carnegie Pharmaceuticals appoints Sunil Shah as the Director of Operations. Mr. Shah previously worked in the operations department for twenty eight years at various capacities and most recently as the Manager of Operations in Sun Pharma (formerly URL Mutual Pharma).

January 2017

Carnegie Pharmaceuticals appoints Ajay Raju, Esq. as Company's Legal Advisor.

Carnegie Pharmaceuticals appoints Indigo Global Corp. as Company's Executive-in-Residence Consultancy partner.

July 2016

Carnegie Pharmaceuticals and Leading Pharma extend their development agreement by one more year.

August 2015

Carnegie Pharmaceuticals initiated the development of following products:

• CP001
• CP002
• CP003
• CP004
• CP005

May 2015

• Carnegie Pharmaceuticals commenced its operations.
• Carnegie Pharmaceuticals hired Mr. Keval Prasad as the Executive Vice President of Analytical Research & Development.

April 2015

• Carnegie Pharmaceuticals signed a four-year agreement to develop ANDAs in collaboration with Leading Pharma, LLC. Under this agreement, Carnegie and Leading are targeting to file 24 products in next four years.
• Carnegie Pharmaceuticals signed a lease for its R&D Center in the Princeton Corporate Plaza located in Monmouth Junction, NJ. Carnegie will start its operations in May 2015.
• Rakesh Grover, Ph.D., founded Carnegie Pharmaceuticals, LLC. Carnegie will be a specialty pharmaceutical company that will develop unique generic products, paragraph IV products and branded products.